Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rdc.2011.02.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute, next-generation AMPK activation initiates a disease-resistant gene expression program in dystrophic skeletal muscle.
FASEB J
May 2023
Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.
Duchenne muscular dystrophy (DMD) is a life-limiting neuromuscular disorder characterized by muscle weakness and wasting. Previous proof-of-concept studies demonstrate that the dystrophic phenotype can be mitigated with the pharmacological stimulation of AMP-activated protein kinase (AMPK). However, first-generation AMPK activators have failed to translate from bench to bedside due to either their lack of potency or toxic, off-target effects.
View Article and Find Full Text PDFPreface to the psoriatic arthritis supplement.
Rheumatology (Oxford)
March 2020
University of Washington School of Medicine, Seattle, WA, USA.
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Breast
April 2020
Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Background: Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e.g., with letrozole.
View Article and Find Full Text PDFPreexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Int J Cancer
October 2019
Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
One of the most common adverse events (AEs) occurring during treatment with aromatase inhibitors (AIs) is musculoskeletal pain. The aim of our study was to analyze the influence of preexisting muscle/limb pain and joint pain on the development of AI-induced musculoskeletal AEs. Women eligible for upfront adjuvant endocrine therapy with letrozole were included in the PreFace study, a multicenter phase IV trial.
View Article and Find Full Text PDFPreface.
Curr Top Dev Biol
February 2019
Myology Group, INSERM, Hopital Pitié Salpêtrière, University of Pierre and Marie Curie, Paris, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!